Benzinga | Sep 27, 2021 11:41AM EDT

Gilead Sciences Issues Statement On New NCCN Clinical Practice Guidelines In Oncology Recommendations For Sacituzumab Govitecan-HZIY In Second-Line And Later Metastatic Triple-Negative Breast Cancer

-Reuters